📣 VC round data is live. Check it out!

Cochlear Valuation Multiples

Discover Cochlear's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Imeik Technology Development, Rigaku, Mirion, Caris Life Sciences and more.

Cochlear Overview

About Cochlear

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.


Founded

1983

HQ

Australia

Employees

5.5K

Financials (LTM)

Revenue: $2B
EBITDA: $350M

EV

$5B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cochlear Financials

Cochlear reported last 12-month revenue of $2B and EBITDA of $350M.

In the same LTM period, Cochlear generated $1B in gross profit, $350M in EBITDA, and $221M in net income.

Revenue (LTM)


Cochlear P&L

In the most recent fiscal year, Cochlear reported revenue of $2B and EBITDA of $444M.

Cochlear is profitable as of last fiscal year, with gross margin of 74%, EBITDA margin of 26%, and net margin of 17%.

See analyst estimates for Cochlear
LTMLast FY202320242025202620272028
Revenue$2B$2B$1B$2B$2B
Gross Profit$1B$1B$1B$1B$1B
Gross Margin72%74%75%74%73%
EBITDA$350M$444M$382M$429M$395M
EBITDA Margin21%26%26%26%24%
EBIT Margin17%20%17%18%17%
Net Profit$221M$279M$235M$267M$249M
Net Margin13%17%16%16%15%

Financial data powered by Morningstar, Inc.

Cochlear Stock Performance

Cochlear has current market cap of $5B, and enterprise value of $5B.

Market Cap Evolution


Cochlear's stock price is $69.31.

Cochlear share price decreased by 4.3% in the last 30 days, and by 67.5% in the last year.

Cochlear has an EPS (earnings per share) of $4.26.

See more trading valuation data for Cochlear
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5B$5B-4.5%-4.3%-42.9%-67.5%$4.26

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cochlear Valuation Multiples

Cochlear trades at 2.7x EV/Revenue multiple, and 13.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Cochlear

EV / Revenue (LTM)


Cochlear Financial Valuation Multiples

As of June 3, 2026, Cochlear has market cap of $5B and EV of $5B.

Cochlear has a P/E ratio of 20.5x.

LTMLast FY202320242025202620272028
EV/Revenue2.7x2.7x3.1x2.8x2.7x
EV/EBITDA13.0x10.3x12.0x10.6x11.6x
EV/EBIT16.0x13.4x17.6x15.6x16.0x
EV/Gross Profit3.8x3.7x4.1x3.8x3.7x
P/E20.5x16.3x19.2x17.0x18.2x
EV/FCF23.5x45.2x22.6x29.4x30.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cochlear Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cochlear Margins & Growth Rates

Cochlear decreased revenue by 0% and EBITDA by 22% in the last fiscal year.

In the most recent fiscal year, Cochlear reported gross margin of 74%, EBITDA margin of 26%, and net margin of 17%.

See estimated margins and future growth rates for Cochlear

Cochlear Margins

Last FY202420252026202720282029
Gross Margin74%74%73%72%
EBITDA Margin26%26%24%22%
EBIT Margin20%18%17%18%
Net Margin17%16%15%14%
FCF Margin6%9%9%13%

Cochlear Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(0%)10%2%2%
Gross Profit Growth(2%)9%0%1%
EBITDA Growth(22%)12%(8%)(6%)
EBIT Growth(18%)13%(3%)6%
Net Profit Growth(22%)13%(7%)(6%)
FCF Growth99%(23%)(4%)52%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cochlear Operational KPIs

Cochlear's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Cochlear's Rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cochlear's Rule of X is 27% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cochlear
LTMLast FY202320242025202620272028
Rule of 4025%24%---
Bessemer Rule of X32%27%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue33%31%31%31%32%
G&A Expenses to Revenue8%9%10%9%8%
R&D Expenses to Revenue13%12%13%12%13%
Opex to Revenue-56%57%56%56%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cochlear Competitors

Cochlear competitors include Imeik Technology Development, Rigaku, Mirion, Caris Life Sciences, APT Medical, BillionToOne, Canon Marketing Japan, Hamamatsu Photonics, LivaNova and Jiangsu Yuyue Medical.

Most Cochlear public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Imeik Technology Development11.0x10.6x17.1x17.8x
Rigaku7.9x7.7x34.1x32.2x
Mirion5.7x5.2x23.0x20.6x
Caris Life Sciences5.3x4.8x31.0x29.5x
APT Medical10.9x9.9x26.8x25.0x
BillionToOne12.9x10.7x105.5x67.9x
Canon Marketing Japan0.9x0.9x8.2x8.2x
Hamamatsu Photonics3.6x3.5x17.8x17.7x

This data is available for Pro users. Sign up to see all Cochlear competitors and their valuation data.

Start Free Trial

Acquisitions by Cochlear

Cochlear has acquired 2 companies to date.

Last acquisition by Cochlear was on April 27th 2022. Cochlear acquired Oticon Medical for $121M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Cochlear

Oticon Medical
Sycle
Description
Oticon Medical is a Smørum, Denmark-headquartered developer of implantable hearing solutions including the Ponto bone-anchored hearing system for conductive hearing loss and single-sided deafness plus the Neuro cochlear implant system for severe-to-profound sensorineural hearing loss. The company distributes products across more than 50 countries through subsidiaries and partners worldwide. Oticon Medical invests in audiological research to advance titanium implant technology and sound processing algorithms. Its solutions integrate with personal audio devices and support active lifestyles for hearing-impaired individuals.
Sycle is a practice management software provider serving audiology and hearing healthcare professionals for over 20 years. Sycle is the industry-leading platform enabling hearing care clinics to manage patient records, scheduling, billing, insurance claims, and managed care. The HIPAA-compliant, scalable solution includes telehealth capabilities, electronic documentation, custom form building, and integrations with hearing test data systems. Features cover the entire patient journey from appointment scheduling and reminders through payment processing and patient communications.
HQ CountryDenmarkUnited States
HQ City
Copenhagen
San Francisco, CA
Deal Date27 Apr 202211 May 2017
Valuation$121M$78M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cochlear acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Cochlear

Cochlear has invested in 3 companies to date.

Latest investment by Cochlear was on August 27th 2021. Cochlear invested in Seer in their $25M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Cochlear

Seer
Nyxoah
Nyxoah
Earlens
Description
Seer Medical is a Melbourne-headquartered medtech firm founded in 2016 that deploys wearable EEG devices for long-term monitoring of neurological disorders like epilepsy. Its cloud-based platform processes ambulatory data with machine learning algorithms to generate clinical insights, reducing diagnostic times from months to days. The company equips over 200 Australian clinics and serves patients across Victoria, New South Wales, and Queensland. Seer Medical has raised more than AUD 50 million in funding from investors including Blackbird Ventures and partners with major hospitals for remote neurodiagnostics.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Earlens is a Hayward-headquartered medical device company offering the Earlens Contact Hearing Solution, FDA-cleared in 2019. The system places a light-driven lens on the eardrum to vibrate it directly, providing wide bandwidth sound reproduction superior to air-conduction hearing aids.
HQ CountryUnited StatesBelgiumBelgiumUnited States
HQ City
Rochester, MN
Mont-Saint-Guibert
Mont-Saint-Guibert
San Francisco, CA
Deal Date27 Aug 202112 Feb 202012 Nov 20185 Jun 2017
RoundSeries AStrategic investmentSeries CSeries C
Raised$25M$28M$17M$73M
InvestorsCochlear; EWM Group; Giant Leap Fund; SG Hiscock and CompanyCochlear; ResMedCochlearAisling Capital; Cochlear; CRG; Lightstone Ventures; Medtronic; New Enterprise Associates; Richard King Mellon Foundation; SightLine Partners; Vertex Ventures; Vertex Ventures HC; Windham Venture Partners
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cochlear investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cochlear

When was Cochlear founded?Cochlear was founded in 1983.
Where is Cochlear headquartered?Cochlear is headquartered in Australia.
How many employees does Cochlear have?As of today, Cochlear has over 5K employees.
Who is the CEO of Cochlear?Cochlear's CEO is Dig Howitt.
Is Cochlear publicly listed?Yes, Cochlear is a public company listed on Australian Securities Exchange.
What is the stock symbol of Cochlear?Cochlear trades under COH ticker.
When did Cochlear go public?Cochlear went public in 1995.
Who are competitors of Cochlear?Cochlear main competitors include Imeik Technology Development, Rigaku, Mirion, Caris Life Sciences, APT Medical, BillionToOne, Canon Marketing Japan, Hamamatsu Photonics, LivaNova, Jiangsu Yuyue Medical.
What is the current market cap of Cochlear?Cochlear's current market cap is $5B.
What is the current revenue of Cochlear?Cochlear's last 12 months revenue is $2B.
What is the current revenue growth of Cochlear?Cochlear revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Cochlear?Current revenue multiple of Cochlear is 2.7x.
What is the current EBITDA of Cochlear?Cochlear's last 12 months EBITDA is $350M.
What is Cochlear's EBITDA margin?Cochlear's last 12 months EBITDA margin is 21%.
What is the current EV/EBITDA multiple of Cochlear?Current EBITDA multiple of Cochlear is 13.0x.
What is the current FCF of Cochlear?Cochlear's last 12 months FCF is $194M.
What is Cochlear's FCF margin?Cochlear's last 12 months FCF margin is 12%.
What is the current EV/FCF multiple of Cochlear?Current FCF multiple of Cochlear is 23.5x.
How many companies Cochlear has acquired to date?As of June 2026, Cochlear has acquired 2 companies.
What was the largest acquisition by Cochlear?$121M acquisition of Oticon Medical on 27th April 2022 was the largest M&A Cochlear has done to date.
What companies Cochlear acquired?Cochlear acquired Oticon Medical and Sycle.
In how many companies Cochlear has invested to date?As of June 2026, Cochlear has invested in 3 companies.
What was the last Cochlear investment?On 27th August 2021 Cochlear invested in Seer, participating in a $25M Series A round, alongside EWM Group, Giant Leap Fund, and SG Hiscock and Company.
In what companies Cochlear invested in?Cochlear invested in Earlens, Nyxoah, and Seer.

See public comps similar to Cochlear

Lists including Cochlear

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial